In Vitro Diagnostics Market Size, Share & Forecast Report - 2026 to 2030

The global in-vitro diagnostics market size is anticipated to register a sustainable CAGR of over 5.5% during the forecast period from 2025 to 2030. The rising adoption of in vitro diagnostics due to the increasing number of IVD tests across the globe is a primary factor to drive the market growth. The rapid growth in chronic and infectious diseases around the world is a major factor to increase the IVD test globally.

The advent of automated in vitro diagnostics systems to provide error-free, accurate, and efficient diagnoses in hospitals and laboratories is expected to fuel the market growth. Furthermore, the increasing interest of major players to launch new in vitro diagnosis products is projected to uplift the market over the forecast period. In addition, the rise in the use of personalized medicines in the treatment of various chronic diseases has also led to a boom in the market.

In various economies, the rapid growth in the older population could be attributed to a decline in fertility and a low birth rate. According to United Nations, in 2017, approximately 960 million people were accounted as over 60 years old across the globe. Moreover, it is estimated that around 137 million people accounted at over 80 years old and it is projected to reach around 425 million by 2027.

Market Outlook:

Industry Trends Shaping the In Vitro Diagnostics Market:

The in-vitro diagnostics (IVD) market is being shaped by the rising demand for early disease detection, personalized medicine, and rapid diagnostic solutions. Growing prevalence of chronic conditions such as cancer, diabetes, and cardiovascular diseases has fueled the adoption of molecular diagnostics, immunoassays, and point-of-care (POC) testing. A major trend is the shift toward molecular and genetic testing, driven by advances in next-generation sequencing (NGS) and companion diagnostics that support targeted therapies. The COVID-19 pandemic further accelerated innovation, normalizing widespread use of rapid tests and creating long-term demand for decentralized testing solutions.

Another key trend is the integration of digital health and advanced technologies into IVD platforms. Artificial intelligence (AI), big data analytics, and cloud-based solutions are being increasingly used to enhance diagnostic accuracy, improve workflow efficiency, and enable real-time decision-making. Point-of-care devices connected through IoT and smartphone applications are expanding access to diagnostics, especially in remote and resource-limited settings. Additionally, regulatory support for innovative diagnostics and rising investment in R&D are fostering the development of multiplex assays, personalized testing solutions, and automated laboratory systems, further transforming the IVD landscape.

In Vitro Diagnostics Market Driver:

• Increasing Prevalence of Chronic and Infectious Diseases: The rising prevalence of chronic and infectious diseases, such as cardiovascular diseases, cancer, diabetes, and infectious diseases like COVID-19, has fueled the demand for diagnostic tests. In vitro diagnostics play a crucial role in disease diagnosis, monitoring, and management, driving the growth of the market.
• Technological Advancements in Diagnostic Testing: Technological advancements in the field of diagnostics have led to the development of innovative and more accurate diagnostic tests. Advances in areas such as molecular diagnostics, immunoassays, point-of-care testing, and genetic testing have improved the sensitivity, specificity, and speed of diagnostic tests, contributing to the market growth.
• Aging Population and Increasing Healthcare Expenditure: The aging population is more susceptible to chronic diseases, necessitating regular diagnostic testing. As the global population ages and healthcare expenditure increases, the demand for in vitro diagnostics is expected to rise. The need for early detection, disease monitoring, and personalized treatment plans are driving the market growth.
• Emphasis on Early Disease Detection and Prevention: Early disease detection is crucial for effective treatment and improved patient outcomes. In vitro diagnostics enable the early detection of diseases, allowing for timely interventions and preventive measures. Increased awareness about the importance of early diagnosis and preventive healthcare has contributed to the growth of the IVD market.
• Growing Adoption of Point-of-Care Testing: Point-of-care testing (POCT) has gained popularity due to its convenience, rapid results, and potential cost savings. POCT allows for testing at the point of patient care, eliminating the need for sample transportation and reducing turnaround time. The increasing adoption of POCT devices in various healthcare settings, including hospitals, clinics, and homecare, has boosted the demand for in vitro diagnostics.
• Rise in Personalized Medicine and Precision Diagnostics: The shift towards personalized medicine and precision diagnostics has created a demand for advanced diagnostic tests. In vitro diagnostics enable the identification of specific biomarkers, genetic mutations, and molecular signatures, aiding in the selection of targeted therapies and personalized treatment plans. The growing focus on precision diagnostics has driven the market growth.
• Increasing Awareness of the Benefits of Early Screening: Public awareness campaigns and initiatives promoting regular health check-ups and early disease screening have increased the demand for diagnostic tests. Governments, healthcare organizations, and advocacy groups have emphasized the importance of early screening and diagnostics for conditions like cancer, cardiovascular diseases, and infectious diseases, stimulating the market growth.
• Favorable Reimbursement Policies and Regulations: Favorable reimbursement policies and regulations supporting the use of in vitro diagnostics have facilitated market growth. Governments and insurance providers recognize the value of diagnostic tests in healthcare decision-making and have implemented reimbursement schemes that cover a wide range of diagnostic procedures. These favorable reimbursement policies have encouraged the adoption of in vitro diagnostics.

In Vitro Diagnostics Market Opportunities:

The in-vitro diagnostics (IVD) market presents major opportunities in the expansion of personalized medicine and precision diagnostics. As healthcare systems increasingly shift toward tailored treatment approaches, there is rising demand for molecular diagnostics, companion diagnostics, and genetic testing to identify patient-specific biomarkers and treatment responses. This creates strong growth prospects for companies developing advanced assays and next-generation sequencing (NGS)-based solutions. Additionally, the growing focus on preventive healthcare and early disease detection—especially for cancer, infectious diseases, and genetic disorders—offers significant opportunities for innovative IVD technologies that improve patient outcomes and reduce healthcare costs.

Another key opportunity lies in the rapid adoption of point-of-care (POC) and digital-enabled diagnostics. Emerging economies in Asia-Pacific, Latin America, and Africa are investing heavily in decentralized healthcare infrastructure, creating demand for portable, affordable, and easy-to-use diagnostic devices. Integration of AI, IoT, and cloud-based platforms into IVD solutions allows for real-time monitoring, data sharing, and telemedicine integration, expanding their role in both clinical and homecare settings. Furthermore, strategic collaborations between diagnostics companies, pharmaceutical firms, and healthcare providers are opening avenues for co-developed solutions that link diagnostics with therapeutics, accelerating innovation and broadening market potential.

Market Segments Insights:

The global in-vitro diagnostics market is bifurcated into the product, technology, application, end-user, and geography. On the basis of product, the market is further segmented into instruments, reagents, and services. The reagents segment held the largest market share in terms of revenue and accounted to hold a major market share around two-third of the market in 2020. The segment growth is attributed to the increasing demand for accurate, rapid, and sensitive devices.

By application, the in vitro diagnostics market is divided into infectious disease, diabetes, oncology, cardiology, and others. The infectious disease segment dominated the market in 2020 by revenue and accounted to hold the largest share of over 40% of the market. The rising incidence of infectious diseases such as HIV, AIDS, COVID-19, and tuberculosis is a major factor to drive the segment growth by application.

The in vitro diagnostics comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2025 to 2030. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

In Vitro Diagnostics Market Segmentation:

By Product:

• Instruments
• Reagents
• Services

By Technology:

• Immunoassay
• Hematology
• Clinical Chemistry
• Molecular Diagnostics
• Coagulation
• Microbiology
• Others

By Application:

• Infectious Disease
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Disease
• Drug testing
• Others

By End-User:

• Hospitals
• Laboratories
• Home Care
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage: North America Holds the Largest Revenue Share of In Vitro Diagnostics Market

Geographically, North America dominated the global in-vitro diagnostics market in 2020 and estimated to hold the largest revenue share of over 40% of the market around the globe. The increasing incidence of infectious diseases, rising awareness of the consumer regarding infectious diseases, and the presence of the major players have contributed to the market growth in the region. Furthermore, the Asia Pacific is accounted to grow at the fastest growth rate over the forecast period due to the increasing awareness of the patients for early tests and the increasing incidence of chronic diseases in the region.

Competition Assessment:

Key players operating in the global in vitro diagnostics market are Abbott, Danaher, bioMerieux SA, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, and Siemens Healthineers AG. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Abbott
• Danaher
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• Siemens Healthineers AG
• QIAGEN
• Quidel Corporation
• Hoffmann-La Roche AG
• Sysmex Corporation
• Agilent Technologies

Key Questions Answered by In Vitro Diagnostics Market Report:

• Global in-vitro diagnostics market forecasts from 2021-2027
• Regional in vitro diagnostics market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• In-vitro diagnostics submarket forecasts from 2021-2027 covering the market by product, by technology, by application, by end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the market